Company Overview - Rapport Therapeutics, Inc. (RAPP) currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy) [3][4] - The company has shown strong price performance, with shares up 9.03% over the past week and 14.97% over the past month, outperforming the Zacks Medical - Biomedical and Genetics industry, which is up 5% and 3.48% respectively [6] Price Performance - Over the past quarter, RAPP shares have risen 24.16%, and over the last year, they are up 44.18%, significantly outperforming the S&P 500, which has moved 6.25% and 14.29% respectively [7] - The average 20-day trading volume for RAPP is 361,157 shares, indicating a bullish trend as the stock is rising with above-average volume [8] Earnings Outlook - In the past two months, 4 earnings estimates for RAPP have moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$3.01 to -$2.79 [10] - For the next fiscal year, 4 estimates have also moved upwards with no downward revisions during the same period, indicating positive sentiment around the company's earnings potential [10] Conclusion - Given the strong momentum indicators and positive earnings outlook, RAPP is positioned as a promising investment opportunity for those seeking stocks with potential for near-term growth [12]
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know